Drug profile · INN
vutrisiran
AMVUTTRA
vutrisiran (AMVUTTRA) is a transthyretin mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Nervous system (N07) N07XX18
Patents linked 0
Pipeline programs 5
News articles 1
Drug details — vutrisiran
- Class
- Nervous system (N07)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
vutrisiran (AMVUTTRA) is a transthyretin mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN vutrisiran
Brand AMVUTTRA
Mechanism Transthyretin mRNA rnai inhibitor
Target Transthyretin mRNA
Therapeutic class Nervous system (N07)
ATC code N07XX18
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Transthyretin mRNA rnai inhibitor
Primary target: Transthyretin mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is vutrisiran?
vutrisiran (AMVUTTRA) is a transthyretin mrna rnai inhibitor. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for vutrisiran?
AMVUTTRA is a marketed brand name for vutrisiran. Check FDA Drugs@FDA for the current US label holder and prescribing information.